OR WAIT null SECS
February 07, 2023
If approved, reproxalap would be the first inhibitor of RASP to treat patients with dry eye disease. The FDA PDUFA date is Nov. 23, 2023.
January 03, 2023
If approved, CSF-1 would be the second therapy to treat patients with presbyopia, or age-related blurry vision.
December 16, 2022
Iyuzeh is a preservative-free formulation of latanoprost and doesn’t need to be stored at refrigerated temperatures. It will be available in the second half of 2023.
November 29, 2022
If approved, reproxalap would be the first inhibitor of RASP, which contributes to ocular inflammation and changes in tear lipid composition.
November 19, 2022
Appellis had submitted updated data for the pegcetacoplan in age-related macular degeneration, which is considered a major amendment to the NDA. The new PDUFA date is Feb. 26, 2023.
October 24, 2022
Novaliq’s CyclASol uses the EyeSol technology that allows for improved bioavailability and better efficacy. The PDUFA target action date set by the FDA is June 8, 2023.
October 12, 2022
The FDA has assigned a target action date of Feb. 11, 2023.
September 27, 2022
Omlonti is approved to reduce elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension
September 06, 2022
If approved, NOV03 would be the first prescription eye drop to address excessive tear evaporation. The FDA has assigned a PDUFA action date of June 28, 2023.
August 10, 2022
Novaliq’s CyclASol uses a new technology that allows cyclosporine to be soluble without water or preservatives.